Global investment firm Bain Capital has offloaded nearly 1% stake in Emcure Pharmaceuticals through open market transactions, raising over Rs 289 crore, according to block deal data on the NSE.
Key Highlights
- Bain Capital sold 0.95% stake in Emcure for Rs 289 crore via NSE block deal.
- Emcure Pharmaceuticals fell 2.31%, trading at Rs 1,690 apiece on NSE post deal.
The transaction saw Bain Capital’s affiliate, BC Investments IV Ltd, sell approximately 18 lakh shares-representing a 0.95% stake-at an average price of Rs 1,608.20 per share. The total deal size stood at Rs 289.47 crore.
Following the stake sale, shares of Emcure Pharmaceuticals declined 2.31%, trading at Rs 1,690 apiece on the National Stock Exchange.
Stake Dilution
Post-transaction, BC Investments IV’s holding in the Pune-based pharmaceutical company has reduced from 3.87% to 2.93%. Interestingly, the entire block was picked up by Government Pension Fund Global, the world’s largest sovereign wealth fund at the same price.
Also Read: Govt Revives IDBI Bank Stake Sale; Rs 80,000 Cr Disinvestment Push
This marks another instance of Bain Capital trimming its stake in the company, following a previous sale of 2.4% equity worth Rs 563 crore in July 2025.
Strong Financial Performance
Emcure Pharmaceuticals has delivered robust financial performance in recent quarters. For the third quarter ended December 31, 2025, the company reported a 48% year-on-year increase in consolidated profit after tax (PAT) to Rs 231 crore, compared to Rs 156 crore in the same period last year.
Revenue from operations also rose significantly to Rs 2,363 crore, up from Rs 1,963 crore a year earlier, driven by strong growth across key business segments.
